Breaking News, Collaborations & Alliances

Q BioMed, SRI Enter ASD Collaboration

To provide formulation development, preclinical development, and early clinical manufacturing of QBM-001 for non-verbal or minimally verbal autistic children

Q BioMed Inc. has entered a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed’s Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children.    SRI has broad expertise in solving formulation, drug delivery, and characterization challenges of small molecule drugs and biologics. The formulation team, led by Dr. Gita Shank...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters